Literature DB >> 11899418

Use of intrathecal trastuzumab in a patient with carcinomatous meningitis.

L R Laufman, K F Forsthoefel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11899418     DOI： 10.1016/S1526-8209(11)70419-0

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN： 1526-8209            Impact factor:   3.225


× No keyword cloud information.
  15 in total

1.  Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies.

Authors:  Javier Puente Vázquez; Sara López-Tarruella Cobo; José A García-Sáenz; Antonio Casado Herráez; Fernando Moreno Antón; Teresa Sampedro Gimeno; Coralia Bueno Muiño; Enrique Grande Pulido; Miguel Martín Jiménez; Eduardo Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2006-01       Impact factor: 3.405

Review 2.  Leptomeningeal metastases from solid malignancy: a review.

Authors:  Sophie Taillibert; Florence Laigle-Donadey; Catherine Chodkiewicz; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

Review 3.  Optimal management of brain metastases from breast cancer. Issues and considerations.

Authors:  Rupert Bartsch; Anna S Berghoff; Matthias Preusser
Journal:  CNS Drugs       Date:  2013-02       Impact factor: 5.749

Review 4.  Revisiting the role of molecular targeted therapies in patients with brain metastases.

Authors:  Dionysis Papadatos-Pastos; Udai Banerji
Journal:  J Neurooncol       Date:  2011-07-22       Impact factor: 4.130

Review 5.  PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer.

Authors:  Parvin F Peddi; Sara A Hurvitz
Journal:  J Neurooncol       Date:  2014-01-28       Impact factor: 4.130

6.  Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma.

Authors:  Cigall Kadoch; Jing Li; Valerie S Wong; Lingjing Chen; Soonmee Cha; Pamela Munster; Clifford A Lowell; Marc A Shuman; James L Rubenstein
Journal:  Clin Cancer Res       Date:  2013-11-04       Impact factor: 12.531

7.  Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.

Authors:  Abraham Boskovitz; Roger E McLendon; Tatsunori Okamura; John H Sampson; Darell D Bigner; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2009-08       Impact factor: 2.408

8.  Leptomeningeal neoplasms.

Authors:  Jan Drappatz; Tracy T Batchelor
Journal:  Curr Treat Options Neurol       Date:  2007-07       Impact factor: 3.598

Review 9.  Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer.

Authors:  A Jo Chien; Hope S Rugo
Journal:  Breast Cancer Res Treat       Date:  2012-11-10       Impact factor: 4.872

10.  Intrathecal Trastuzumab Treatment of the Neoplastic Meningitis due to Breast Cancer: A Case Report and Review of the Literature.

Authors:  Cristina Dumitrescu; Dominique Lossignol
Journal:  Case Rep Oncol Med       Date:  2013-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.